Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).
Jeffrey Clarke(Duke Medical Center), Edward F. Patz(G1 Therapeutics (United States)), Hirva Mamdani(Wayne State University), Lin Gu(Cancer Research And Biostatistics), Jeffrey Crawford(Duke Medical Center), Scott Antonia(Parker Institute for Cancer Immunotherapy), Guru Sonpavde(AdventHealth Orlando), Michael J. Campa(Duke University), Neal Ready(Duke University), Ryan T. Bushey(Pennsylvania State University), George R. Simon(Ohio Department of Health), Elizabeth B. Gottlin(Duke University), Tom Stinchcombe(Duke Medical Center), James E. Herndon(Duke University)
Cited by 4
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656